Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 1/2024

15-06-2022 | Cardiomyopathy | Review Article

Therapeutic Strategies Targeting Mitochondrial Dysfunction in Sepsis-induced Cardiomyopathy

Authors: Oluwabukunmi Modupe Salami, Olive Habimana, Jin-fu Peng, Guang-Hui Yi

Published in: Cardiovascular Drugs and Therapy | Issue 1/2024

Login to get access

Abstract

Sepsis is an increasingly worldwide problem; it is currently regarded as a complex life-threatening dysfunction of one or more organs as a result of dysregulated host immune response to infections. The heart is one of the most affected organs, as roughly 10% to 70% of sepsis cases are estimated to turn into sepsis-induced cardiomyopathy (SIC). SIC can be defined as a reversible myocardial dysfunction characterized by dilated ventricles, impaired contractility, and decreased ejection fraction. Mitochondria play a critical role in the normal functioning of cardiac tissues as the heart is highly dependent on its production of adenosine triphosphate (ATP), its damage during SIC includes morphology impairment, mitophagy, biogenesis disequilibrium, electron transport chain disturbance, molecular damage from the actions of pro-inflammatory cytokines and many other different impairments that are major contributing factors to the severity of SIC. Although mitochondria-targeted therapies usage is still inadequate in clinical settings, the preclinical study outcomes promise that the implementation of these therapies may effectively treat SIC. This review summarizes the different therapeutic strategies targeting mitochondria structure, quality, and quantity abnormalities for the treatment of SIC.
Literature
1.
Wasyluk W, Nowicka-Stążka P, Zwolak A. Heart Metabolism in Sepsis-Induced Cardiomyopathy—Unusual Metabolic Dysfunction of the Heart. Int J Environ Res Public Health. 2021;18(14):7598.PubMedPubMedCentralCrossRef
2.
Donnino MW, Andersen LW, Chase M, et al. Randomized, double-blind, placebo-controlled trial of thiamine as a metabolic resuscitator in septic shock: a pilot study. Crit Care Med. 2016;44(2):360.PubMedPubMedCentralCrossRef
3.
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.PubMedPubMedCentralCrossRef
4.
5.
6.
Rackow E, Kaufman B, Falk J, Astiz M, Weil M. Hemodynamic response to fluid repletion in patients with septic shock: evidence for early depression of cardiac performance. Circ Shock. 1987;22(1):11–22.PubMed
7.
Martin L, Derwall M, Al Zoubi S, et al. The septic heart: current understanding of molecular mechanisms and clinical implications. Chest. 2019;155(2):427–37.PubMedCrossRef
8.
Tsolaki V, Makris D, Mantzarlis K, Zakynthinos E. Sepsis-induced cardiomyopathy: oxidative implications in the initiation and resolution of the damage. Oxidative Medicine and Cellular Longevity. 2017;2017.
9.
10.
Jarczak D, Kluge S, Nierhaus A. Sepsis-Pathophysiology and Therapeutic Concepts. Front Med (Lausanne). 2021;8:628302.PubMedCrossRef
11.
Zang Q, Maass DL, Tsai SJ, Horton JW. Cardiac mitochondrial damage and inflammation responses in sepsis. Surg Infect. 2007;8(1):41–54.CrossRef
12.
Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. 2021;18(6):424–34.PubMedCrossRef
13.
Sato R, Kuriyama A, Takada T, Nasu M, Luthe SK. Prevalence and risk factors of sepsis-induced cardiomyopathy: A retrospective cohort study. Medicine (Baltimore). 2016;95(39):e5031.PubMedCrossRef
14.
Jeong HS, Lee TH, Bang CH, Kim JH, Hong SJ. Risk factors and outcomes of sepsis-induced myocardial dysfunction and stress-induced cardiomyopathy in sepsis or septic shock: A comparative retrospective study. Medicine (Baltimore). 2018;97(13):e0263.PubMedCrossRef
15.
L’Heureux M, Sternberg M, Brath L, Turlington J, Kashiouris MG. Sepsis-Induced Cardiomyopathy: a Comprehensive Review. Curr Cardiol Rep. 2020;22(5):35.PubMedPubMedCentralCrossRef
16.
Mekontso Dessap A, Razazi K, Brun-Buisson C, Deux J-F. Myocardial viability in human septic heart. Intensive Care Med. 2014;40(11):1746–8.PubMedCrossRef
17.
Charpentier J, Luyt C-E, Fulla Y, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med. 2004;32(3):660–5.PubMedCrossRef
18.
Mehta NJ, Khan IA, Gupta V, et al. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol. 2004;95(1):13–7.PubMedCrossRef
19.
Werdan K, Oelke A, Hettwer S, et al. Septic cardiomyopathy: hemodynamic quantification, occurrence, and prognostic implications. Clin Res Cardiol. 2011;100(8):661–8.PubMedCrossRef
20.
Sato R, Nasu M. A review of sepsis-induced cardiomyopathy. J Intensive Care. 2015;3(1):1–7.CrossRef
21.
Zangrillo A, Putzu A, Monaco F, et al. Levosimendan reduces mortality in patients with severe sepsis and septic shock: a meta-analysis of randomized trials. J Crit Care. 2015;30(5):908–13.PubMedCrossRef
22.
Schlesinger JJ, Burger CF. Methylene Blue for Acute Septic Cardiomyopathy in a Burned Patient. J Burn Care Res. 2016;37(3):e287–91.PubMedCrossRef
23.
Fan Y, Jiang M, Gong D, Zou C. Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials. Sci Rep. 2016;6:25984.ADSPubMedPubMedCentralCrossRef
24.
Krishnan K, Wassermann TB, Tednes P, Bonderski V, Rech MA. Beyond the bundle: Clinical controversies in the management of sepsis in emergency medicine patients. Am J Emerg Med. 2022;51:296–303.PubMedCrossRef
25.
Vogel DJ, Murray J, Czapran AZ, et al. Veno-arterio-venous ECMO for septic cardiomyopathy: a single-centre experience. Perfusion. 2018;33(1_suppl):57–64.
26.
Alvarez S, Vico T, Vanasco V. Cardiac dysfunction, mitochondrial architecture, energy production, and inflammatory pathways: Interrelated aspects in endotoxemia and sepsis. Int J Biochem Cell Biol. 2016;81:307–14.PubMedCrossRef
27.
Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie. 2002;84(2–3):153–66.PubMedCrossRef
28.
Bernardi P, Di Lisa F. The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection. J Mol Cell Cardiol. 2015;78:100–6.PubMedPubMedCentralCrossRef
29.
Bernardi P, Krauskopf A, Basso E, et al. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J. 2006;273(10):2077–99.PubMedCrossRef
30.
31.
Larche J, Lancel S, Hassoun SM, et al. Inhibition of mitochondrial permeability transition prevents sepsis-induced myocardial dysfunction and mortality. J Am Coll Cardiol. 2006;48(2):377–85.PubMedCrossRef
32.
Pan P, Zhang H, Su L, Wang X, Liu D. Melatonin balance the autophagy and apoptosis by regulating UCP2 in the LPS-induced cardiomyopathy. Molecules. 2018;23(3):675.PubMedPubMedCentralCrossRef
33.
Fauvel H, Marchetti P, Obert G, et al. Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats. Am J Respir Crit Care Med. 2002;165(4):449–55.PubMedCrossRef
34.
Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84(1):277–359.PubMedCrossRef
35.
Hu Y, Yan JB, Zheng MZ, et al. Mitochondrial aldehyde dehydrogenase activity protects against lipopolysaccharide-induced cardiac dysfunction in rats. Mol Med Rep. 2015;11(2):1509–15.PubMedCrossRef
36.
MacGarvey NC, Suliman HB, Bartz RR, et al. Activation of mitochondrial biogenesis by heme oxygenase-1–mediated NF-E2–related factor-2 induction rescues mice from lethal Staphylococcus aureus sepsis. Am J Respir Crit Care Med. 2012;185(8):851–61.PubMedPubMedCentralCrossRef
37.
Durand A, Duburcq T, Dekeyser T, et al. Involvement of mitochondrial disorders in septic cardiomyopathy. Oxidative medicine and cellular longevity. 2017;2017.
38.
Liang D, Huang A, Jin Y, et al. Protective effects of exogenous NaHS against sepsis-induced myocardial mitochondrial injury by enhancing the PGC-1α/NRF2 pathway and mitochondrial biosynthesis in mice. American J Transl Res. 2018;10(5):1422.
39.
Rahmel T, Marko B, Nowak H, et al. Mitochondrial dysfunction in sepsis is associated with diminished intramitochondrial TFAM despite its increased cellular expression. Sci Rep. 2020;10(1):1–11.ADSCrossRef
40.
Carré JE, Orban J-C, Re L, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med. 2010;182(6):745–51.PubMedPubMedCentralCrossRef
41.
Nagy G, Koncz A, Perl A. T cell activation-induced mitochondrial hyperpolarization is mediated by Ca2+-and redox-dependent production of nitric oxide. J Immunol. 2003;171(10):5188–97.PubMedCrossRef
42.
Suliman HB, Piantadosi CA. Mitochondrial quality control as a therapeutic target. Pharmacol Rev. 2016;68(1):20–48.PubMedCrossRef
43.
Lancel S, Hassoun SM, Favory R, et al. Carbon monoxide rescues mice from lethal sepsis by supporting mitochondrial energetic metabolism and activating mitochondrial biogenesis. J Pharmacol Exp Ther. 2009;329(2):641–8.PubMedCrossRef
44.
Wang X, Qin W, Qiu X, et al. A novel role of exogenous carbon monoxide on protecting cardiac function and improving survival against sepsis via mitochondrial energetic metabolism pathway. Int J Biol Sci. 2014;10(7):777.PubMedPubMedCentralCrossRef
45.
Suliman HB, Carraway MS, Tatro LG, Piantadosi CA. A new activating role for CO in cardiac mitochondrial biogenesis. J Cell Sci. 2007;120(2):299–308.PubMedCrossRef
46.
Mattingly KA, Ivanova MM, Riggs KA, et al. Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis. Mol Endocrinol. 2008;22(3):609–22.PubMedCrossRef
47.
Li Y, Feng Y-F, Liu X-T, et al. Songorine promotes cardiac mitochondrial biogenesis via Nrf2 induction during sepsis. Redox Biol. 2021;38:101771.PubMedCrossRef
48.
Hondares E, Pineda-Torra I, Iglesias R, et al. PPARδ, but not PPARα, activates PGC-1α gene transcription in muscle. Biochem Biophys Res Commun. 2007;354(4):1021–7.PubMedCrossRef
49.
Yang Y, Zhu Y, Xiao J, et al. Maresin conjugates in tissue regeneration 1 prevents lipopolysaccharide-induced cardiac dysfunction through improvement of mitochondrial biogenesis and function. Biochem Pharmacol. 2020;177:114005.PubMedCrossRef
50.
Sánchez-Villamil JP, D’Annunzio V, Finocchietto P, et al. Cardiac-specific overexpression of thioredoxin 1 attenuates mitochondrial and myocardial dysfunction in septic mice. Int J Biochem Cell Biol. 2016;81:323–34.PubMedCrossRef
51.
Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127(6):1109–22.PubMedCrossRef
52.
Xin T, Lu C. SirT3 activates AMPK-related mitochondrial biogenesis and ameliorates sepsis-induced myocardial injury. Aging (Albany NY). 2020;12(16):16224.PubMedCrossRef
53.
Russell LK, Mansfield CM, Lehman JJ, et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator-1α promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004;94(4):525–33.PubMedCrossRef
54.
Stanzani G, Duchen MR, Singer M. The role of mitochondria in sepsis-induced cardiomyopathy. Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease. 2019;1865(4):759–73.PubMedCrossRef
55.
Ni H-M, Williams JA, Ding W-X. Mitochondrial dynamics and mitochondrial quality control. Redox Biol. 2015;4:6–13.PubMedCrossRef
56.
Marín-García J, Akhmedov AT. Mitochondrial dynamics and cell death in heart failure. Heart Fail Rev. 2016;21(2):123–36.PubMedCrossRef
57.
Jin J-Y, Wei X-X, Zhi X-L, Wang X-H, Meng D. Drp1-dependent mitochondrial fission in cardiovascular disease. Acta Pharmacologica Sinica. 2021;42(5):655–64.PubMedCrossRef
58.
Ishihara T, Ban-Ishihara R, Maeda M, et al. Dynamics of mitochondrial DNA nucleoids regulated by mitochondrial fission is essential for maintenance of homogeneously active mitochondria during neonatal heart development. Mol Cell Biol. 2015;35(1):211–23.PubMedCrossRef
59.
60.
Disatnik MH, Ferreira JC, Campos JC, et al. Acute inhibition of excessive mitochondrial fission after myocardial infarction prevents long-term cardiac dysfunction. J Am Heart Assoc. 2013;2(5):e000461.PubMedPubMedCentralCrossRef
61.
Zhou H, Zhang Y, Hu S, et al. Melatonin protects cardiac microvasculature against ischemia/reperfusion injury via suppression of mitochondrial fission-VDAC 1-HK 2-mPTP-mitophagy axis. J Pineal Res. 2017;63(1):e12413.PubMedPubMedCentralCrossRef
62.
Hernandez-Resendiz S, Prunier F, Girao H, et al. Targeting mitochondrial fusion and fission proteins for cardioprotection. J Cell Mol Med. 2020;24(12):6571–85.PubMedPubMedCentralCrossRef
63.
Zang QS, Sadek H, Maass DL, et al. Specific inhibition of mitochondrial oxidative stress suppresses inflammation and improves cardiac function in a rat pneumonia-related sepsis model. American J Physiol-Heart Circ Physiol. 2012;302(9):H1847–59.CrossRef
64.
Wu Y, Yao Y-M, Lu Z-Q. Mitochondrial quality control mechanisms as potential therapeutic targets in sepsis-induced multiple organ failure. J Mol Med. 2019;97(4):451–62.PubMedCrossRef
65.
Gonzalez AS, Elguero ME, Finocchietto P, et al. Abnormal mitochondrial fusion–fission balance contributes to the progression of experimental sepsis. Free Radical Res. 2014;48(7):769–83.CrossRef
66.
67.
Wu D, Dasgupta A, Chen KH, et al. Identification of novel dynamin-related protein 1 (Drp1) GTPase inhibitors: Therapeutic potential of Drpitor1 and Drpitor1a in cancer and cardiac ischemia-reperfusion injury. FASEB J. 2020;34(1):1447–64.PubMedCrossRef
68.
Tan Y, Ouyang H, Xiao X, Zhong J, Dong M. Irisin ameliorates septic cardiomyopathy via inhibiting DRP1-related mitochondrial fission and normalizing the JNK-LATS2 signaling pathway. Cell Stress Chaperones. 2019;24(3):595–608.PubMedPubMedCentralCrossRef
69.
Yu W, Mei X, Zhang Q, et al. Yap overexpression attenuates septic cardiomyopathy by inhibiting DRP1-related mitochondrial fission and activating the ERK signaling pathway. J Recept Signal Transduct Res. 2019;39(2):175–86.PubMedCrossRef
70.
Pride CK, Mo L, Quesnelle K, et al. Nitrite activates protein kinase A in normoxia to mediate mitochondrial fusion and tolerance to ischaemia/reperfusion. Cardiovasc Res. 2014;101(1):57–68.CrossRef
71.
Bian X, Xu J, Zhao H, et al. Zinc-induced SUMOylation of dynamin-related protein 1 protects the heart against ischemia-reperfusion injury. Oxidative medicine and cellular longevity. 2019;2019.
72.
Ikeda Y, Shirakabe A, Maejima Y, et al. Endogenous Drp1 mediates mitochondrial autophagy and protects the heart against energy stress. Circ Res. 2015;116(2):264–78.PubMedCrossRef
73.
Wang J, Zhou H. Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia–reperfusion injury. Acta Pharmaceutica Sinica B. 2020;10(10):1866–79.PubMedPubMedCentralCrossRef
74.
Song Z, Ghochani M, McCaffery JM, Frey TG, Chan DC. Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol Biol Cell. 2009;20(15):3525–32.PubMedPubMedCentralCrossRef
75.
Ferreira JCB, Campos JC, Qvit N, et al. A selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats. Nat Commun. 2019;10(1):329.ADSPubMedPubMedCentralCrossRef
76.
77.
Burke N, Hall AR, Hausenloy DJ. OPA1 in Cardiovascular Health and Disease. Curr Drug Targets. 2015;16(8):912–20.PubMedCrossRef
78.
Huang J, Li R, Wang C. The Role of Mitochondrial Quality Control in Cardiac Ischemia/Reperfusion Injury. Oxidative Med Cellular Longevity. 2021;2021.
79.
Neuspiel M, Zunino R, Gangaraju S, Rippstein P, McBride H. Activated mitofusin 2 signals mitochondrial fusion, interferes with Bax activation, and reduces susceptibility to radical induced depolarization. J Biol Chem. 2005;280(26):25060–70.PubMedCrossRef
80.
Papanicolaou KN, Khairallah RJ, Ngoh GA, et al. Mitofusin-2 maintains mitochondrial structure and contributes to stress-induced permeability transition in cardiac myocytes. Mol Cell Biol. 2011;31(6):1309–28.PubMedPubMedCentralCrossRef
81.
Dorn GW, Clark CF, Eschenbacher WH, et al. MARF and Opa1 control mitochondrial and cardiac function in Drosophila. Circ Res. 2011;108(1):12–7.PubMedCrossRef
82.
Chen L, Liu T, Tran A, et al. OPA 1 Mutation and Late-Onset Cardiomyopathy: Mitochondrial Dysfunction and mtDNA Instability. J Am Heart Assoc. 2012;1(5):e003012.PubMedPubMedCentralCrossRef
83.
Merkwirth C, Dargazanli S, Tatsuta T, et al. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev. 2008;22(4):476–88.PubMedPubMedCentralCrossRef
84.
Zhang Y, Wang Y, Xu J, et al. Melatonin attenuates myocardial ischemia-reperfusion injury via improving mitochondrial fusion/mitophagy and activating the AMPK-OPA1 signaling pathways. J Pineal Res. 2019;66(2):e12542.PubMedCrossRef
85.
Maneechote C, Palee S, Kerdphoo S, et al. Balancing mitochondrial dynamics via increasing mitochondrial fusion attenuates infarct size and left ventricular dysfunction in rats with cardiac ischemia/reperfusion injury. Clin Sci. 2019;133(3):497–513.CrossRef
86.
Shen T, Zheng M, Cao C, et al. Mitofusin-2 is a major determinant of oxidative stress-mediated heart muscle cell apoptosis. J Biol Chem. 2007;282(32):23354–61.PubMedCrossRef
87.
Ong S-B, Subrayan S, Lim SY, et al. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121(18):2012–22.PubMedCrossRef
88.
Boyman L, Karbowski M, Lederer WJ. Regulation of Mitochondrial ATP Production: Ca2+ Signaling and Quality Control. Trends Mol Med. 2020;26(1):21–39.PubMedCrossRef
89.
Brealey D, Singer M. Mitochondrial dysfunction in sepsis. Current Infectious Disease Rep. 2003;5(5):365–71.CrossRef
90.
91.
Giacalone M, Martinelli R, Abramo A, et al. Rapid reversal of severe lactic acidosis after thiamine administration in critically ill adults: a report of 3 cases. Nutr Clin Pract. 2015;30(1):104–10.PubMedCrossRef
92.
Escames G, López LC, Ortiz F, et al. Attenuation of cardiac mitochondrial dysfunction by melatonin in septic mice. FEBS J. 2007;274(8):2135–47.PubMedCrossRef
93.
Galley HF, Lowes DA, Allen L, et al. Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. J Pineal Res. 2014;56(4):427–38.PubMedPubMedCentralCrossRef
94.
McCall CE, Zabalawi M, Liu T, et al. Pyruvate dehydrogenase complex stimulation promotes immunometabolic homeostasis and sepsis survival. JCI insight. 2018;3:15.CrossRef
95.
Stacpoole PW, Wright EC, Baumgartner TG, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. N Engl J Med. 1992;327(22):1564–9.PubMedCrossRef
96.
Eyenga P, Roussel D, Rey B, et al. Mechanical ventilation preserves diaphragm mitochondrial function in a rat sepsis model. Intensive Care Med Exp. 2021;9(1):19.PubMedPubMedCentralCrossRef
97.
Geng N, Ren L, Xu L, Zou D, Pang W. Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2021;21(1):488.PubMedPubMedCentralCrossRef
98.
Bank HV, Hurtado-Thiele M, Oshimura N, Simcox J. Mitochondrial Lipid Signaling and Adaptive Thermogenesis. Metabolites. 2021;11(2):124.CrossRef
99.
Xie C, Zhang Y, Tran TD, et al. Irisin controls growth, intracellular Ca2+ signals, and mitochondrial thermogenesis in cardiomyoblasts. PLoS ONE. 2015;10(8):e0136816.PubMedPubMedCentralCrossRef
100.
Kong X, Wang R, Xue Y, et al. Sirtuin 3, a new target of PGC-1α, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS ONE. 2010;5(7):e11707.ADSPubMedPubMedCentralCrossRef
101.
102.
103.
Chen Huang J-D, Lyu S-L, Liu J-J, Zeng C, Q-Y. Correlation between uncoupling protein 2 expression and myocardial mitochondrial injury in rats with sepsis induced by lipopolysaccharide Zhongguo dang dai er ke za zhi. Chinese J Contemporary Pediatr. 2016;18(2):159–64.
104.
Huang J, Peng W, Zheng Y, et al. Upregulation of UCP2 expression protects against LPS-induced oxidative stress and apoptosis in cardiomyocytes. Oxidative medicine and cellular longevity. 2019;2019.
105.
Zheng G, Lyu J, Liu S, et al. Silencing of uncoupling protein 2 by small interfering RNA aggravates mitochondrial dysfunction in cardiomyocytes under septic conditions. Int J Mol Med. 2015;35(6):1525–36.PubMedPubMedCentralCrossRef
106.
Chen Y, Chen G, Zhang J, et al. Uncoupling protein 2 facilitates insulin-elicited protection against lipopolysaccharide-induced myocardial dysfunction. Mater Express. 2020;10(3):337–49.CrossRef
107.
Kovacic P, Pozos RS, Somanathan R, Shangari N, O’Brien PJ. Mechanism of mitochondrial uncouplers, inhibitors, and toxins: focus on electron transfer, free radicals, and structure-activity relationships. Curr Med Chem. 2005;12(22):2601–23.PubMedCrossRef
108.
Supale S, Li N, Brun T, Maechler P. Mitochondrial dysfunction in pancreatic β cells. Trends Endocrinol Metab. 2012;23(9):477–87.PubMedCrossRef
109.
110.
Ganten D, Ruckpaul K. Encyclopedic reference of genomics and proteomics in molecular medicine. Springer; 2006.
111.
Kumar S, Gupta E, Srivastava VK, et al. Nitrosative stress and cytokines are linked with the severity of sepsis and organ dysfunction. Br J Biomed Sci. 2019;76(1):29–34.PubMedCrossRef
112.
MatÉs JM, Pérez-Gómez C, De Castro IN. Antioxidant enzymes and human diseases. Clin Biochem. 1999;32(8):595–603.PubMedCrossRef
113.
Supinski GS, Callahan LA. Polyethylene glycol–superoxide dismutase prevents endotoxin-induced cardiac dysfunction. Am J Respir Crit Care Med. 2006;173(11):1240–7.PubMedPubMedCentralCrossRef
114.
Liu Y, Yang W, Sun X, et al. SS31 ameliorates sepsis-induced heart injury by inhibiting oxidative stress and inflammation. Inflammation. 2019;42(6):2170–80.PubMedCrossRef
115.
Wang Z, Bu L, Yang P, Feng S, Xu F. Alleviation of sepsis-induced cardiac dysfunction by overexpression of Sestrin2 is associated with inhibition of p-S6K and activation of the p-AMPK pathway. Mol Med Rep. 2019;20(3):2511–8.PubMedPubMedCentral
116.
Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science. 2004;304(5670):596–600.ADSPubMedCrossRef
117.
Abitagaoglu S, Akinci S, Saricaoglu F, et al. Effect of Coenzyme Q10 on Organ Damage in Sepsis. Bratisl Lek Listy. 2015;116(7):433–9.PubMed
118.
Soltani R, Alikiaie B, Shafiee F, Amiri H, Mousavi S. Coenzyme Q10 improves the survival and reduces inflammatory markers in septic patients. Bratisl Lek Listy. 2020;121(2):154–8.PubMed
119.
Lowes DA, Thottakam BM, Webster NR, Murphy MP, Galley HF. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic Biol Med. 2008;45(11):1559–65.PubMedCrossRef
120.
Kokkinaki D, Hoffman M, Kalliora C, et al. Chemically synthesized Secoisolariciresinol diglucoside (LGM2605) improves mitochondrial function in cardiac myocytes and alleviates septic cardiomyopathy. J Mol Cell Cardiol. 2019;127:232–45.PubMedPubMedCentralCrossRef
121.
Mattox TA, Psaltis C, Weihbrecht K, et al. Prohibitin-1 Is a Dynamically Regulated Blood Protein With Cardioprotective Effects in Sepsis. J Am Heart Assoc. 2021;10(14):e019877.PubMedPubMedCentralCrossRef
122.
Lee M-T, Jung S-Y, Baek MS, Shin J, Kim W-Y. Early Vitamin C, Hydrocortisone, and Thiamine Treatment for Septic Cardiomyopathy: A Propensity Score Analysis. J Personalized Med. 2021;11(7):610.CrossRef
123.
Hobai IA, Edgecomb J, LaBarge K, Colucci WS. Dysregulation of intracellular calcium transporters in animal models of sepsis induced cardiomyopathy. Shock (Augusta, Ga). 2015;43(1):3.PubMedCrossRef
124.
Hassoun SM, Marechal X, Montaigne D, et al. Prevention of endotoxin-induced sarcoplasmic reticulum calcium leak improves mitochondrial and myocardial dysfunction. Crit Care Med. 2008;36(9):2590–6.PubMedCrossRef
125.
Joseph LC, Kokkinaki D, Valenti M-C, et al. Inhibition of NADPH oxidase 2 (NOX2) prevents sepsis-induced cardiomyopathy by improving calcium handling and mitochondrial function. JCI insight. 2017;2:17.CrossRef
126.
Zhou Q, Xie M, Zhu J, et al. PINK1 Contained in huMSCs-Exosomes Prevents Cardiomyocyte Mitochondrial Calcium Overload in Sepsis by Recovering Mitochondrial Ca2+ Efflux. 2020.
127.
Wang L, Wei Y. The Improvements of Cardiac Calcium Handing and Cardiomyopathy in Septic Rats via Nos Signaling by Neuregulin-1. Circulation. 2018;138(Suppl_1):A11603-A.
128.
Wiewel MA, Van Vught LA, Scicluna BP, et al. Prior use of calcium channel blockers is associated with decreased mortality in critically ill patients with sepsis: a prospective observational study. Crit Care Med. 2017;45(3):454–63.PubMedCrossRef
129.
Shang X, Lin K, Yu R, et al. Resveratrol Protects the Myocardium in Sepsis by Activating the Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway and Inhibiting the Nuclear Factor-κB (NF-κB) Signaling Pathway. Med Sci Monit. 2019;25:9290–8.PubMedPubMedCentralCrossRef
130.
Smeding L, Leong-Poi H, Hu P, et al. Salutary effect of resveratrol on sepsis-induced myocardial depression. Crit Care Med. 2012;40(6):1896–907.PubMedCrossRef
131.
132.
133.
Kung CT, Hsiao SY, Tsai TC, et al. Plasma nuclear and mitochondrial DNA levels as predictors of outcome in severe sepsis patients in the emergency room. J Transl Med. 2012;10:130.PubMedPubMedCentralCrossRef
134.
Jung SS, Moon JS, Xu JF, et al. Carbon monoxide negatively regulates NLRP3 inflammasome activation in macrophages. Am J Physiol Lung Cell Mol Physiol. 2015;308(10):L1058–67.PubMedPubMedCentralCrossRef
135.
136.
137.
Yao X, Carlson D, Sun Y, et al. Mitochondrial ROS Induces Cardiac Inflammation via a Pathway through mtDNA Damage in a Pneumonia-Related Sepsis Model. PLoS ONE. 2015;10(10):e0139416.PubMedPubMedCentralCrossRef
138.
139.
140.
141.
142.
Hertz NT, Berthet A, Sos ML, et al. A neo-substrate that amplifies catalytic activity of parkinson’s-disease-related kinase PINK1. Cell. 2013;154(4):737–47.PubMedPubMedCentralCrossRef
143.
144.
Geisler S, Holmström KM, Skujat D, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010;12(2):119–31.PubMedCrossRef
145.
Ordureau A, Sarraf SA, Duda DM, et al. Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. Mol Cell. 2014;56(3):360–75.PubMedPubMedCentralCrossRef
146.
Sedlackova L, Korolchuk VI. Mitochondrial quality control as a key determinant of cell survival. Biochimica et Biophysica Acta (BBA)-Molecular Cell Res. 2019;1866(4):575–87.CrossRef
147.
Wei Y, Chiang WC, Sumpter R, et al. Prohibitin 2 Is an Inner Mitochondrial Membrane Mitophagy Receptor. Cell. 2017;168(1–2):224-38.e10.PubMedCrossRef
148.
Yun J, Puri R, Yang H, et al. MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin. Elife. 2014;3:e01958.PubMedPubMedCentralCrossRef
149.
Cadete VJ, Vasam G, Menzies KJ, Burelle Y. 2019 Mitochondrial quality control in the cardiac system An integrative view. Biochimica et Biophysica Acta (BBA)-Molecular Basis Disease. 1865;4:782–96.
150.
Liu L, Feng D, Chen G, et al. Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat Cell Biol. 2012;14(2):177–85.PubMedCrossRef
151.
152.
Zhang J, Ney PA. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ. 2009;16(7):939–46.PubMedCrossRef
153.
Murakawa T, Yamaguchi O, Hashimoto A, et al. Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates mitophagy and mitochondrial fragmentation. Nat Commun. 2015;6:7527.ADSPubMedCrossRef
154.
Chu CT, Ji J, Dagda RK, et al. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat Cell Biol. 2013;15(10):1197–205.PubMedPubMedCentralCrossRef
155.
Zhang E, Zhao X, Zhang L, et al. Minocycline promotes cardiomyocyte mitochondrial autophagy and cardiomyocyte autophagy to prevent sepsis-induced cardiac dysfunction by Akt/mTOR signaling. Apoptosis. 2019;24(3):369–81.PubMedCrossRef
156.
Cao Y, Han X, Pan H, et al. Emerging protective roles of shengmai injection in septic cardiomyopathy in mice by inducing myocardial mitochondrial autophagy via caspase-3/Beclin-1 axis. Inflamm Res. 2020;69(1):41–50.PubMedCrossRef
157.
158.
Wang S, Zhao Z, Feng X, et al. Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition. J Cell Mol Med. 2018;22(10):5132–44.PubMedPubMedCentralCrossRef
159.
Hsieh C-H, Pai P-Y, Hsueh H-W, Yuan S-S, Hsieh Y-C. Complete induction of autophagy is essential for cardioprotection in sepsis. Ann Surg. 2011;253(6):1190–200.PubMedCrossRef
160.
Jiang X, Cai S, Jin Y, et al. Irisin Attenuates Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis in the H9C2 Cellular Model of Septic Cardiomyopathy through Augmenting Fundc1-Dependent Mitophagy. Oxidative Medicine and Cellular Longevity. 2021;2021.
161.
Bian X, Teng T, Zhao H, et al. Zinc prevents mitochondrial superoxide generation by inducing mitophagy in the setting of hypoxia/reoxygenation in cardiac cells. Free Radical Res. 2018;52(1):80–91.CrossRef
162.
Jang S-y, Kang HT, Hwang ES. Nicotinamide-induced mitophagy: event mediated by high NAD+/NADH ratio and SIRT1 protein activation. J Biological Chemistry. 2012;287(23):19304–14.CrossRef
163.
Ji W, Wan T, Zhang F, et al. Aldehyde Dehydrogenase 2 Protects Against Lipopolysaccharide-Induced Myocardial Injury by Suppressing Mitophagy. Front Pharmacol. 2021;12:1025.CrossRef
164.
Roshanravan B, Liu SZ, Ali AS, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS ONE. 2021;16(7):e0253849.PubMedPubMedCentralCrossRef
165.
Hortmann M, Robinson S, Mohr M, et al. The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2019;8(8):695–702.PubMedCrossRef
166.
Daubert MA, Yow E, Dunn G, et al. Novel mitochondria-targeting peptide in heart failure treatment a randomized, placebo-controlled trial of elamipretide. Circ Heart Failure. 2017;10(12):e004389.PubMedCrossRef
167.
Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–87.PubMedCrossRef
168.
Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96(3):576–82.PubMedCrossRef
169.
Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310(16):1683–91.PubMedCrossRef
170.
Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017;151(6):1229–38.PubMedCrossRef
171.
Antcliffe DB, Santhakumaran S, Orme RML, et al. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Med. 2019;45(10):1392–400.PubMedCrossRef
172.
Kim WY, Baek MS, Kim YS, et al. Glucose-insulin-potassium correlates with hemodynamic improvement in patients with septic myocardial dysfunction. J Thorac Dis. 2016;8(12):3648–57.PubMedPubMedCentralCrossRef
173.
Hernandez G, Bruhn A, Luengo C, et al. Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study. Intensive Care Med. 2013;39(8):1435–43.PubMedCrossRef
174.
Kopterides P, Falagas M. Statins for sepsis: a critical and updated review. Clin Microbiol Infect. 2009;15(4):325–34.PubMedCrossRef
Metadata
Title
Therapeutic Strategies Targeting Mitochondrial Dysfunction in Sepsis-induced Cardiomyopathy
Authors
Oluwabukunmi Modupe Salami
Olive Habimana
Jin-fu Peng
Guang-Hui Yi
Publication date
15-06-2022
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 1/2024
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-022-07354-8

Other articles of this Issue 1/2024

Cardiovascular Drugs and Therapy 1/2024 Go to the issue

Review Article

Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers

Invited Editorial

Dapagliflozin for Atrial Fibrillation

Original Article

Effect of Clinical and Genetic Factors on the Development of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG) in Egyptian Patients Receiving Beta-Blockers

Original Article

The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding

Original Article

Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis

Original Article

Effect of Dapagliflozin on the Outcome of Radiofrequency Catheter Ablation in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation